Livid over Lipids No Longer; Alnylam, Tekmira Find Peace

Alnylam Pharmaceuticals Inc.'s eleventh-hour settlement with Tekmira Pharmaceuticals Corp. leaves Alnylam $65 million lighter but still in strong financial shape, without losing rights to access the Lipid NanoParticle (LNP) delivery technology important for its RNAi work.